Eleison Seeks Phase III Success with Glufosfamide
By Marie Powers
Tuesday, October 8, 2013
Eleison Pharmaceuticals LLC moved lead compound glufosfamide into a Phase III study in second-line pancreatic cancer, seeking to achieve success in a drug that was a near-miss in previous hands.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.